Key facts
- RICOVR Healthcare’s last known valuation is $18.0M (Feb 2026).
- It has raised $7.2M across 7 recorded rounds; the latest was Seed Round ($550K) in Dec 2025.
- Notable investors include New Jersey Economic Development Authority, Achari Ventures, Floret Ventures, HALLEY Venture Partners, HBS Alumni Angels of Greater New York — 9 tracked in total.
- RICOVR Healthcare has filed 6 Form Ds with the SEC since 2020, most recently Dec 2023 ($2.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for RICOVR Healthcare
Funding rounds
7 roundsAbout RICOVR Healthcare
Developer of a saliva-based biosensor testing device designed to support rapid and non-invasive point-of-care diagnostics. The company offers a saliva-based detection platform with quantitative biomarker analysis and fast processing, enabling employers, healthcare providers, and law enforcement to conduct accurate testing without invasive procedures.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2018
- Employees
- 10
- Website
- ricovr.com/
- Ownership
- Privately Held (backing)
RICOVR Healthcare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RICOVR Healthcare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RICOVR Healthcare in its N-PORT filings yet. We sweep new filings monthly.